Sorry for delay in reply.
Re your question about price weakness, there has not been a business update for a while. Bioventix business highly dependent upon take up of Siemens kit by health professionals. Not in Bioventix hands.
This business is highly profitable, but it is priced in for growth!
A great set of financials, as previously guided. Healthy dividend pay out including a special divi, gives an annualised payout of around 3.5%, based on current share price. A business with sales revenue up by 30+% with no cost increase is certainly an attractive animal.
It would appear that use of the Siemens kit have not taken off yet and the level of growth in sales of this diagnostic test in the coming year will influence whether the overall BVXP growth can be sustained.
Revenue to 30th June 2017 is expected to be marginally in excess of £7m and that due to the cost base follow a similar shallow trajectory as in previous years, both revenues and profits are expected to be ahead of market expectations. ShareScope and Stockopedia forecasts were for revenue of £6.3m and pre-tax profits of £4.9m. In excess of £7M is a considerable hike on top of the forecasts - in excess of 11% as the precise figure above the £7M not yet known. One could assume pre-tax profits and earnings per share to be well ahead and significantly more than expectations - possibly circa 30% rather than the 17% forecast. The implications for the cash pile and dividend are clear.
Going forward given that they described the launch of a new test by Siemens for troponin, a key biomarker used in heart attack diagnostics, as significant' for the company and that this was announced early in May so has had only a matter of weeks to make contributions to the FY ending 30 June this augurs well for the current year when it will contribute for the full 52 weeks.
Quite right, as long as they keep increasing revenue, profits and dividend, the share price is a bit of an irrelevance to me - at least till it starts getting to be too large a proportion of my portfolio.
The Company Secretary's reply to me, then was wrong. Maybe they had not quite finished bean counting at that stage, and indications were revenue was going to be within the range of expectations, but now they've got further, things look a little better so they had to release the up date.
As you say, good news.
So if the EPS is around 90 there is still a lot of growth built into the share price - probably quite rightly, but maybe there is an expectation of a better dividend hike too, though it will still only be a yield of around 2.5%.
Last year they issued a trading update on 22nd August. I wrote to the company secretary to ask if we could expect a similar one this year.
He replied promptly (always a good sign) to say last year they had to issue one because the results were going to be considerably better than forecast. This year they are likely to be in line with forecasts, so no trading statement will be issued. The Finals will be in October.
Current forecast (from Digital Look)
Pre-tax profits £4.9m
So at current prices that puts us on a PE of 27.3 & a yield of 2.4%: not cheap, but for the speed of growth, not overly expensive.
"Stockmarket valuations often drift in the traditionally quiet summer months, and this year is no exception. But after taking a breather in recent weeks, smaller-cap indices are beginning to pick up again - and this bullish move is being led by ..."
Much much better than that. Louis B Meyer (who built MGM into the largest film studio in the world in the 30s was a successful business man before he went into films. He could not believe his luck. Here was an industry where you make a product once and can sell it time and time again. Brilliant.
Bioventix is just as good. You sell a product then earn further money every time it is used.
Can you imagine selling a TV then earning more money every time it is switched on?
This is a business where every employee could go home on full pay, and the company would still make a profit. (We might need a book keeper to keep tabs on things.)
I'm not sure if any client ever challenged the in perpetuity clause that it would stand up; but as long as they are reliant on BVXP for existing and future products, and for collaborative research, they will happily carry on paying because it's such a small cost in the overall scheme to them.
I wish I had bought more when I first discovered them.
Just to add to my post, Bioventix's figures in recent years have not been skewed by exceptional items. If one looks at the fundamentals page & the bar charts for sales, profit, EPS, dividend etc. one sees a steady smooth progression.
Now putting today's interim figures into perspective. These interims are comparable to the full year results for 2014. Turnover is comparable, this interim dividend is bigger than 2014's final dividend, Net assets are up over 50%, net cash is up 33%; and the most important figures - the profit is larger. So in 2.5 years, the business's value is around doubled. That's equivalent to a compound interest of around 32% p.a.
Important message from the Financial Conduct Authority:
Posting inside information that is not public knowledge, or information that is false or misleading, may constitute market abuse.
This could lead to an unlimited fine and up to seven years in prison.
If you have any information, concerns or queries about market abuse, click here.
The content of the messages posted represents the opinions of the author, and does not represent the opinions of Interactive Investor Trading Limited or its affiliates and has not been approved or issued by Interactive Investor Trading Limited.
You should be aware that the other participants of the above discussion group are strangers to you and may make statements which may be misleading, deceptive or wrong.
Please remember that the value of investments or income from them may go down as well as up and that the past performance of an investment is not a guide to its performance in the future.
The discussion boards on this site are intended to be an information sharing forum and is not intended to address your particular requirements.
Whilst information provided on them can help with your investment research you need to consider carefully whether you should make (or refraining from making) investment or other decisions based on what you see without doing further research on investments you are interested in.
Participating in this forum cannot be a substitute for obtaining advice from an appropriate expert independent adviser who takes into account your circumstances and specific investment needs in selected investments that are appropriate for you.